These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12783585)

  • 1. Pharmacotherapy of hormone refractory prostate cancer: new developments and challenges.
    Rosenbaum E; Carducci MA
    Expert Opin Pharmacother; 2003 Jun; 4(6):875-87. PubMed ID: 12783585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New targeted therapies in hormone-refractory prostate cancer].
    Oudard S; Banu E; Scotte F; Beuzeboc P; Guyader C; Medioni J
    Bull Cancer; 2007 Jul; 94(7 Suppl):F62-8. PubMed ID: 17845995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy for hormone-refractory prostate cancer.
    Shelley M; Harrison C; Coles B; Staffurth J; Wilt TJ; Mason MD
    Cochrane Database Syst Rev; 2006 Oct; (4):CD005247. PubMed ID: 17054249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy of hormone refractory prostate cancer: new standards, new trends].
    Wülfing C; Bierer S; Bögemann M; Piechota H; Hertle L
    Aktuelle Urol; 2005 Aug; 36(4):342-8. PubMed ID: 16110408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newer therapies in advanced prostate cancer.
    Hegeman RB; Liu G; Wilding G; McNeel DG
    Clin Prostate Cancer; 2004 Dec; 3(3):150-6. PubMed ID: 15636681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current trials using bone-targeting agents in prostate cancer.
    Tu SM; Lin SH
    Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palliative treatment of bone metastases in hormone-refractory prostate cancer: effects of pamidronate on the carboxyterminal telopeptide of type-I collagen level in patients with increasing prostate-specific antigen levels.
    Kawashima H; Tanaka T; Kuratsukuri K; Uchida J; Sugimura K; Tamada S; Nishisaka N; Kumata K; Iwai Y; Ikemoto S; Ezaki K; Nakatani T
    Urol Int; 2007; 78(4):345-50. PubMed ID: 17495494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of the spectrum of hormone refractory prostate cancer.
    Clarke NW
    Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular-targeted therapy for hormone-refractory prostate cancer].
    Nishimura K; Takayama H; Nakayama M; Nonomura N; Okuyama A
    Hinyokika Kiyo; 2006 Jun; 52(6):487-90. PubMed ID: 16848363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
    Hussain M; Tangen CM; Lara PN; Vaishampayan UN; Petrylak DP; Colevas AD; Sakr WA; Crawford ED;
    J Clin Oncol; 2005 Dec; 23(34):8724-9. PubMed ID: 16314632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological treatments for prostate cancer.
    Walczak JR; Carducci MA
    Expert Opin Investig Drugs; 2002 Dec; 11(12):1737-48. PubMed ID: 12457434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
    Berry W; Eisenberger M
    Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer.
    Vordos D; Paule B; Vacherot F; Allory Y; Salomon L; Hoznek A; Yiou R; Chopin D; Abbou CC; de la Taille A
    BJU Int; 2004 Sep; 94(4):524-7. PubMed ID: 15329105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of patients with hormone refractory prostate cancer.
    Muthuramalingam SR; Patel K; Protheroe A
    Clin Oncol (R Coll Radiol); 2004 Dec; 16(8):505-16. PubMed ID: 15630842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment options for hormone-refractory prostate cancer].
    Heidenreich A; Ohlmann CH
    Urologe A; 2005 Nov; 44(11):1303-4, 1306-14. PubMed ID: 16237541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of bisphosphonates on bone metastasis of hormone-refractory prostate cancer].
    Tanaka T; Kawashima H; Kuratsukuri K; Sugimura K; Nakatani T
    Hinyokika Kiyo; 2006 Jun; 52(6):491-4. PubMed ID: 16848364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials in metastatic prostate cancer--has there been real progress in the past decade?
    Bhandari MS; Petrylak DP; Hussain M
    Eur J Cancer; 2005 Apr; 41(6):941-53. PubMed ID: 15808960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Present status and perspectives in the treatment of hormone-refractory prostate cancer.
    Silvestris N; Leone B; Numico G; Lorusso V; De Lena M
    Oncology; 2005; 69(4):273-82. PubMed ID: 16282706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promising novel cytotoxic agents and combinations in metastatic prostate cancer.
    Bradley DA; Hussain M
    Cancer J; 2008; 14(1):15-9. PubMed ID: 18303478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent progress in management of advanced prostate cancer.
    Kantoff P
    Oncology (Williston Park); 2005 Apr; 19(5):631-6. PubMed ID: 15945343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.